Dr. Bartlett’s Published Protocol in Globaljournals.org
A 2020 publication in Global Journal of Science Frontier Research titled “SARS-Cov-2 and the Case for Empirical Treatment” written by Doctors Richard Bartlett and Alexandria Watkins represented an “outpatient case study that examines two patients in the United States with unique cases that involve oncology and Severe Acute Respiratory Syndrome Coronavirus-2 (SARSCoV- 2), also known as COVID-19.”
The study “affirmed that an empirical treatment protocol with nebulized budesonide and the efficacy of treating symptomatic patients earlier rather than later has significant implications.” The treatment plan even became “more effective by increasing the dosage and frequency of nebulized budesonide,” according to the authors.
A successful empirical treatment plan included 0.5mg of nebulized budesonide “twice daily” and “clarithromycin (Biaxin) 500mg tab twice daily for ten days, Zinc 50mg tab twice daily, and aspirin 81mg tab daily.” Bartlett’s paper noted that there is a “decreased risk of pneumonia in COPD patients who use nebulized budesonide.”
Secondary bacterial infection of the lung (pneumonia) was extremely common in patients with COVID-19, according to a report from Northwestern Medicine, 3 citing data from an April 2023 study in The Journal of Clinical Investigation.